Company profile
Viridian Therapeutics, Inc.\DE
NASDAQ:VRDNBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Elegrobart | phase3 | — | 4 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06384547 | phase3 | completed | 2024-05-23 | 2025-05-01 | Viridian Therapeutics, Inc. | A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED) |
| NCT06812325 | phase3 | active_not_recruiting | 2025-02-03 | 2026-04-22 | Viridian Therapeutics, Inc. | A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED) |
| NCT07155668 | phase3 | completed | 2025-07-01 | 2026-05-28 | Viridian Therapeutics, Inc. | A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED) |
| NCT05176639 | phase3 | completed | 2022-11-16 | 2024-07-15 | Viridian Therapeutics, Inc. | A Safety, Tolerability, and Efficacy Study of Veligrotug (VRDN 001) in Participants With Thyroid Eye Disease (TED) |
| NCT06625411 | phase3 | active_not_recruiting | 2024-08-27 | 2026-02-12 | Viridian Therapeutics, Inc. | An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED) |
FDA applications (1)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| BLA 761530 | BLA | Viridian Therapeutics, Inc. | ||||
Loading… | ||||||